Capricor Therapeutics (NASDAQ:CAPR) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note published on Monday,Benzinga reports. They currently have a $77.00 price target on the biotechnology company’s stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $12.22 on Monday. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The company has a market capitalization of $555.64 million, a P/E ratio of -11.53 and a beta of 4.10. The company has a 50-day simple moving average of $14.05 and a 200 day simple moving average of $14.50.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. As a group, equities analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Large investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. boosted its holdings in shares of Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after buying an additional 1,345 shares during the period. Russell Investments Group Ltd. lifted its position in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth approximately $68,000. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth approximately $78,000. Finally, New York State Common Retirement Fund grew its position in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 5,000 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.